582 related articles for article (PubMed ID: 29368626)
21. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.
De Nicolo A; Tancredi M; Lombardi G; Flemma CC; Barbuti S; Di Cristofano C; Sobhian B; Bevilacqua G; Drapkin R; Caligo MA
Clin Cancer Res; 2008 Jul; 14(14):4672-80. PubMed ID: 18628483
[TBL] [Abstract][Full Text] [Related]
22. Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer.
Kim H; Cho DY; Choi DH; Jung GH; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Gil WH; Kim SW
Cancer Res Treat; 2016 Jul; 48(3):955-61. PubMed ID: 26790966
[TBL] [Abstract][Full Text] [Related]
23. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
Sung PL; Wen KC; Chen YJ; Chao TC; Tsai YF; Tseng LM; Qiu JT; Chao KC; Wu HH; Chuang CM; Wang PH; Huang CF
PLoS One; 2017; 12(9):e0185615. PubMed ID: 28961279
[TBL] [Abstract][Full Text] [Related]
24. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer.
Paulo P; Maia S; Pinto C; Pinto P; Monteiro A; Peixoto A; Teixeira MR
PLoS Genet; 2018 Apr; 14(4):e1007355. PubMed ID: 29659569
[TBL] [Abstract][Full Text] [Related]
25. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
26. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.
Seal S; Thompson D; Renwick A; Elliott A; Kelly P; Barfoot R; Chagtai T; Jayatilake H; Ahmed M; Spanova K; North B; McGuffog L; Evans DG; Eccles D; ; Easton DF; Stratton MR; Rahman N
Nat Genet; 2006 Nov; 38(11):1239-41. PubMed ID: 17033622
[TBL] [Abstract][Full Text] [Related]
27. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.
Easton DF; Lesueur F; Decker B; Michailidou K; Li J; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Dennis J; Ahmad J; Thompson ER; Damiola F; Pertesi M; Voegele C; Mebirouk N; Robinot N; Durand G; Forey N; Luben RN; Ahmed S; Aittomäki K; Anton-Culver H; Arndt V; ; Baynes C; Beckman MW; Benitez J; Van Den Berg D; Blot WJ; Bogdanova NV; Bojesen SE; Brenner H; Chang-Claude J; Chia KS; Choi JY; Conroy DM; Cox A; Cross SS; Czene K; Darabi H; Devilee P; Eriksson M; Fasching PA; Figueroa J; Flyger H; Fostira F; García-Closas M; Giles GG; Glendon G; González-Neira A; Guénel P; Haiman CA; Hall P; Hart SN; Hartman M; Hooning MJ; Hsiung CN; Ito H; Jakubowska A; James PA; John EM; Johnson N; Jones M; Kabisch M; Kang D; ; Kosma VM; Kristensen V; Lambrechts D; Li N; ; Lindblom A; Long J; Lophatananon A; Lubinski J; Mannermaa A; Manoukian S; Margolin S; Matsuo K; Meindl A; Mitchell G; Muir K; ; Nevelsteen I; van den Ouweland A; Peterlongo P; Phuah SY; Pylkäs K; Rowley SM; Sangrajrang S; Schmutzler RK; Shen CY; Shu XO; Southey MC; Surowy H; Swerdlow A; Teo SH; Tollenaar RA; Tomlinson I; Torres D; Truong T; Vachon C; Verhoef S; Wong-Brown M; Zheng W; Zheng Y; Nevanlinna H; Scott RJ; Andrulis IL; Wu AH; Hopper JL; Couch FJ; Winqvist R; Burwinkel B; Sawyer EJ; Schmidt MK; Rudolph A; Dörk T; Brauch H; Hamann U; Neuhausen SL; Milne RL; Fletcher O; Pharoah PD; Campbell IG; Dunning AM; Le Calvez-Kelm F; Goldgar DE; Tavtigian SV; Chenevix-Trench G
J Med Genet; 2016 May; 53(5):298-309. PubMed ID: 26921362
[TBL] [Abstract][Full Text] [Related]
28. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.
Suszynska M; Ratajska M; Kozlowski P
J Ovarian Res; 2020 May; 13(1):50. PubMed ID: 32359370
[TBL] [Abstract][Full Text] [Related]
29. Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer.
Song H; Ramus SJ; Kjaer SK; Hogdall E; Dicioccio RA; Whittemore AS; McGuire V; Hogdall C; Jacobs IJ; Easton DF; Ponder BA; Dunning AM; Gayther SA; Pharoah PD
PLoS One; 2007 Mar; 2(3):e268. PubMed ID: 17342202
[TBL] [Abstract][Full Text] [Related]
30. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
[TBL] [Abstract][Full Text] [Related]
31. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
Kleiblova P; Stolarova L; Krizova K; Lhota F; Hojny J; Zemankova P; Havranek O; Vocka M; Cerna M; Lhotova K; Borecka M; Janatova M; Soukupova J; Sevcik J; Zimovjanova M; Kotlas J; Panczak A; Vesela K; Cervenkova J; Schneiderova M; Burocziova M; Burdova K; Stranecky V; Foretova L; Machackova E; Tavandzis S; Kmoch S; Macurek L; Kleibl Z
Int J Cancer; 2019 Oct; 145(7):1782-1797. PubMed ID: 31050813
[TBL] [Abstract][Full Text] [Related]
32. Identification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer.
Rump A; Benet-Pages A; Schubert S; Kuhlmann JD; Janavičius R; Macháčková E; Foretová L; Kleibl Z; Lhota F; Zemankova P; Betcheva-Krajcir E; Mackenroth L; Hackmann K; Lehmann J; Nissen A; DiDonato N; Opitz R; Thiele H; Kast K; Wimberger P; Holinski-Feder E; Emmert S; Schröck E; Klink B
PLoS Genet; 2016 Aug; 12(8):e1006248. PubMed ID: 27504877
[TBL] [Abstract][Full Text] [Related]
33. Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy.
Silvestri V; Rizzolo P; Falchetti M; Zanna I; Masala G; Bianchi S; Palli D; Ottini L
Breast Cancer Res Treat; 2011 Apr; 126(2):539-43. PubMed ID: 21165771
[TBL] [Abstract][Full Text] [Related]
34. BRIP-1 germline mutation and its role in colon cancer: presentation of two case reports and review of literature.
Ali M; Delozier CD; Chaudhary U
BMC Med Genet; 2019 May; 20(1):75. PubMed ID: 31064327
[TBL] [Abstract][Full Text] [Related]
35. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia.
Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M
J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582
[TBL] [Abstract][Full Text] [Related]
36. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.
Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E
Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266
[TBL] [Abstract][Full Text] [Related]
37. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
[TBL] [Abstract][Full Text] [Related]
38. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
[TBL] [Abstract][Full Text] [Related]
39. The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?
Teixeira N; van der Hout A; Oosterwijk JC; Vos JR; ; Devilee P; van Engelen K; Meijers-Heijboer H; van der Luijt RB; Kriege M; Mensenkamp AR; Rookus MA; van Roozendaal KE; Mourits MJE; de Bock GH
Eur J Hum Genet; 2018 Jun; 26(6):848-857. PubMed ID: 29483665
[TBL] [Abstract][Full Text] [Related]
40. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
Suszynska M; Klonowska K; Jasinska AJ; Kozlowski P
Gynecol Oncol; 2019 May; 153(2):452-462. PubMed ID: 30733081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
